Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Reckitt and Glaxo walk away from Pfizer’s $20bn auction

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
US -listed Pfizer has been shunned by consumer goods specialist Reckitt Benckiser (RB.) and drugs giant GlaxoSmithKline (GSK) after both firms decided not to bid for its $20bn consumer healthcare division.
Reckitt Benckiser walked away as the consumer healthcare business did not fit its ‘acquisition criteria’ and a partial takeover was not possible. Investors approved the decision, marking its shares 4.8% higher to £58.95 on the news (22 Mar).
Investec analyst Eddy Hargreaves supports Reckitt Benckiser’s decision amid concerns about growth in the consumer healthcare industry.
‘Even an acquisition of part of the portfolio could have necessitated an equity issue or a near fire-sale of part of its home and hygiene business,’ comments Hargreaves.
Shares in GlaxoSmithKline nudged 3.3% to £13.15 after it too confirmed its decision not to make a bid for Pfizer’s unit.
GlaxoSmithKline chief executive Emma Walmsley said any acquisitions ‘must meet our criteria for returns and not compromise our priorities for capital allocation’.
Investors had been worried that Glaxo’s dividend would be cut if it had bought the Pfizer operations as debt would have risen significantly.
In a subsequent move, Glaxo announced on 27 March that it would buy out the partner in its own consumer healthcare joint venture, Novartis. It says this will strengthen operational cash flows and enable the business to better plan for capital allocation in the future, namely money to be used as a priority for pharmaceutical research and development. (LMJ)
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.